Annals of Clinical Neurophysiology

The Korean Society of Clinical Neurophysiology (대한임상신경생리학회)
권호 표지
DOI QR코드

DOI QR Code

Lumbosacral polyradiculoneuropathy associated with combination therapy of nivolumab and ipilimumab

  • Cho, Eun Bin (Department of Neurology, Gyeongsang National University Changwon Hospital) ;
  • Kim, Seung Joo (Department of Neurology, Gyeongsang National University Changwon Hospital) ;
  • Yang, Tae-Won (Department of Neurology, Gyeongsang National University Changwon Hospital) ;
  • Jung, Seunguk (Department of Neurology, Gyeongsang National University Changwon Hospital) ;
  • Jeong, Heejeong (Department of Neurology, Gyeongsang National University Changwon Hospital) ;
  • Park, Ki-Jong (Department of Neurology, Gyeongsang National University Changwon Hospital)
  • Received : 2022.03.14
  • Accepted : 2022.03.21
  • Published : 2022.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Immune checkpoint inhibitors (ICIs) have emerged as one of the most promising therapeutic options for advanced cancers. While ICIs have improved survival in multiple cancers, their increased use is restricted by various immune-related adverse events. In this report we describe a patient with renal cell carcinoma who received a combination of ICIs, nivolumab plus ipilimumab, and who developed lumbosacral polyradiculoneuropathy. Corticosteroid use was an effective treatment for this patient.

Keywords

References

  1. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 2016;39:98-106. https://doi.org/10.1097/COC.0000000000000239
  2. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-915. https://doi.org/10.1038/nm1100
  3. Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ 2018;363:k4226.
  4. Astaras C, de Micheli R, Moura B, Hundsberger T, Hottinger AF. Neurological adverse events associated with immune checkpoint inhibitors: diagnosis and management. Curr Neurol Neurosci Rep 2018;18:3. https://doi.org/10.1007/s11910-018-0810-1
  5. Sheng IY, Ornstein MC. Ipilimumab and nivolumab as first-line treatment of patients with renal cell carcinoma: the evidence to date. Cancer Manag Res 2020;12:4871-4881. https://doi.org/10.2147/CMAR.S202017
  6. Quhal F, Mori K, Bruchbacher A, Resch I, Mostafaei H, Pradere B, et al. First-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol Oncol 2021;4:755-765. https://doi.org/10.1016/j.euo.2021.03.001
  7. Okada K, Seki M, Yaguchi H, Sakuta K, Mukai T, Yamada S, et al. Polyradiculoneuropathy induced by immune checkpoint inhibitors: a case series and review of the literature. J Neurol 2021;268:680-688. https://doi.org/10.1007/s00415-020-10213-x